获取途径

作者

高 尚 李文敬 刘莹莹 李湘奇 许兴超

作者单位

山东中医药大学第一临床医学院，山东 济南 山东第一医科大学研究生院，山东 泰安 山东第一医科大学第二附属医院乳腺外科，山东 泰安 山东第一医科大学第二附属医院乳腺外科，山东 泰安

刊名

Advances in Clinical Medicine

年份

2025

卷号

Vol.15 No.1

页码

1404-1412

ISSN

2161-8712

关键词

乳腺癌 新辅助治疗 疗效 不良反应 Breast Cancer Neoadjuvant Therapy Therapeutic Effect Adverse Reactions

摘要

Objective: To observe the therapeutic effect of the TAC regimen combined with neoadjuvant endocrine therapy in HR-positive/HER-2-negative breast cancer. Methods: A total of 125 patients with HR-positive/HER-2-negative breast cancer from September 2020 to June 2024 were selected and divided into an observation group and a control group . The observation group was further divided into premenopausal and postmenopausal subgroups according to menstrual status. The control group received 6 cycles of ...更多

Objective: To observe the therapeutic effect of the TAC regimen combined with neoadjuvant endocrine therapy in HR-positive/HER-2-negative breast cancer. Methods: A total of 125 patients with HR-positive/HER-2-negative breast cancer from September 2020 to June 2024 were selected and divided into an observation group and a control group . The observation group was further divided into premenopausal and postmenopausal subgroups according to menstrual status. The control group received 6 cycles of TAC chemotherapy, and the observation group received endocrine therapy in addition to TAC chemotherapy. Surgery was performed after 6 cycles of neoadjuvant therapy. The MP grade, pathological complete response rate, objective response rate , change value of Ki-67, and incidence of adverse reactions were analyzed and compared between the observation group and the control group, within the observation groups, and between the observation group and the control group in different pathological stages. Results: There was no significant difference in the pCR rate between the observation group and the control group. The ORR of the observation group was higher than that of the control group , with a significant difference . The change value of Ki-67 in the observation group was greater than that in the control group , with a significant difference . The incidence of hot flashes in the observation group was higher than that in the control group. In the observation group, the objective response rate in Stage II was higher than that in Stage III , and the difference was statistically significant . The change value of Ki-67 in Stage II of the observation group was greater than that in Stage III , and the difference was statistically significant . There was no statistical difference in the remaining results. There was no difference in the results between premenopausal and postmenopausal patients within the observation group. Conclusion: Chemotherapy combined with neoadjuvant endocrine therapy can improve the ORR, improve the MP grade, and reduce Ki-67 in HR-positive/HER-2-negative breast cancer, with good safety.收起

文献类型

期刊

浏览量

4